Key statistics
On Monday, Royalty Pharma PLC (RPD:FRA) closed at 36.51, -3.16% below its 52-week high of 37.70, set on Feb 06, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 37.35 |
|---|---|
| High | 37.35 |
| Low | 36.51 |
| Bid | 36.17 |
| Offer | 37.99 |
| Previous close | 37.70 |
| Average volume | 215.60 |
|---|---|
| Shares outstanding | 577.24m |
| Free float | 387.93m |
| P/E (TTM) | 25.54 |
| Market cap | 25.77bn USD |
| EPS (TTM) | 1.75 USD |
| Annual div (ADY) | 0.7955 EUR |
|---|---|
| Annual div yield (ADY) | 2.11% |
| Div ex-date | Nov 14 2025 |
| Div pay-date | Dec 10 2025 |
| Next div ex-date | Feb 20 2026 |
| Next div pay-date | Mar 10 2026 |
Data delayed at least 15 minutes, as of Feb 09 2026 14:49 GMT.
More ▼
Announcements
- Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
- Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
- Royalty Pharma Announces Dividend Increase
- Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
- Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
- Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma Reports Third Quarter 2025 Results
- Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
More ▼
